Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05572814
Other study ID # 59648
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 30, 2022
Est. completion date December 31, 2023

Study information

Verified date September 2022
Source American College of Cardiology
Contact Lindsey C Hill
Phone 2026754144
Email lhill2@acc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This initiative supports a quality improvement effort evaluating the use of strategies (including technology-based decision support, referral to a virtual GDMT team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular (CV) events among patients with cardiovascular diseases of heart failure, atrial fibrillation and type 2 diabetes (T2D)/ASCVD with a specific focus on underserved populations and those with a history of health care disparities.


Description:

TRANSFORM3 is a Quality Improvement initiative conducted in parallel to the current TRANSFORM CVRiD study and aligned with its goals of using a real-world population study to enable the American College of Cardiology Foundation ("ACCF") to better identify impactful ways to improve guideline directed medical therapy for patients. TRANSFORM3 is focused on improving GDMT use in underserved patients and patients with a history of health care disparities who have one or more of the following: heart failure, atrial fibrillation, and ASCVD/Type 2 diabetes. There is a significant disconnect between increasing availability of effective and safe therapeutics that significantly reduce CV event risk in patients with Heart Failure, T2D and ASCVD, and Atrial Fibrillation-and clear guideline recommendations endorsing these therapies-but very low adoption in clinical practice with the majority of eligible patients that are most likely to benefit from these therapies not receiving them. A high proportion of patients have more than one of these conditions further reducing the chances of receiving optimal guideline directed medical therapy and avoiding the CV events they are designed to prevent.


Recruitment information / eligibility

Status Recruiting
Enrollment 750
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: 1. Age =18 years 2. Personal access to a computer and/or Smartphone for app download 3. Heart Failure (reduced and preserved ejection fraction) AND/OR 4. Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR 5. T2D and ASCVD, defined as follows: 1. Known CAD, prior ACS, or coronary artery revascularization 2. Prior TIA/stroke or known carotid or intracerebral atherosclerosis 3. Prior PAD including requiring revascularization Exclusion Criteria: All patients 1. Current or anticipated participation in an interventional clinical trial of a drug/device 2. Currently receiving comfort care or enrolled in hospice 3. Life expectancy <1 year 4. Pregnancy or active breastfeeding 5. Current or anticipated participation in an interventional clinical trial (other than TRANSFORM3 GDMT) 6. Patients without a clinical encounter within three years of study start date Heart Failure patients: 1. History of or plan for heart transplantation or left ventricular assist de-vice 2. Palliative chronic inotropic therapy 3. NYHA Class 4 heart failure Atrial Fibrillation patients: 1. Current prescription for OAC 2. Reversible cause of atrial fibrillation, such as post-cardiothoracic surgery or thyrotoxicosis 3. History of ischemic stroke in prior 7 days 4. Transient ischemic attack in prior 3 days 5. Platelet count <70,000/ml 6. Hemoglobin concentration <8g/dl 7. History of or condition associated with increased bleeding risk, such as hemophilia 8. Major surgical procedure or trauma within 14 days 9. Clinically significant gastrointestinal bleeding within 8 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Decision Support
Prompts will be provided to clinicians signaling gaps in guideline-directed care
Referral
Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team

Locations

Country Name City State
United States Cardiology Center of Amarillo Amarillo Texas

Sponsors (1)

Lead Sponsor Collaborator
American College of Cardiology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record. GDMT baseline to 9 month change in average composite endpoint of receiving the main classes of drugs (50% or higher of target doses for HF) among eligible patients. We're aiming to see a change or increase in guideline-directed care where there was an original gap. 9 months
Secondary Quality of Life Outcome-MMA-4 Difference in patient reported outcomes on Morisky Medication Adherence Scale (MMAS-4) from baseline, 3 and at 9 months. Study duration up to 1 year.
Secondary Quality of Life Outcome-KCCQ-12 Difference in patient-reported outcome/KCCQ-12 scores from baseline to 9 months (applicable to HFrEF and HFpEF study cohorts only). Study duration up to 1 year.
Secondary Quality of Life Outcome-PAM Difference in patient reported outcomes on Patient Activation MeasureĀ® (PAM) from baseline, 3 and at 9 months. Study duration up to 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Completed NCT04549181 - Problem-Solving for Rural Heart Failure Dyads N/A